|
Volumn 3, Issue 9, 2008, Pages 949-950
|
Editorial: The risk-benefit balance of varenicline for smoking cessation
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIDEPRESSANT AGENT;
BENZODIAZEPINE;
NARCOTIC ANALGESIC AGENT;
PSYCHOTROPIC AGENT;
VARENICLINE;
BENZAZEPINE DERIVATIVE;
QUINOXALINE DERIVATIVE;
ACCIDENT;
BEHAVIOR CHANGE;
CLINICAL PRACTICE;
CLINICAL TRIAL;
COMORBIDITY;
CONVULSION;
DEPRESSION;
DRUG FATALITY;
DRUG SAFETY;
EDITORIAL;
FOOD AND DRUG ADMINISTRATION;
HEALTH BEHAVIOR;
HEART ARRHYTHMIA;
HUMAN;
INJURY;
MENTAL DISEASE;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
SIDE EFFECT;
SMOKING CESSATION;
SUICIDAL BEHAVIOR;
SUICIDAL IDEATION;
TOBACCO DEPENDENCE;
UNSPECIFIED SIDE EFFECT;
VISUAL DISORDER;
METHODOLOGY;
RISK ASSESSMENT;
BENZAZEPINES;
HUMANS;
QUINOXALINES;
RISK ASSESSMENT;
SMOKING CESSATION;
|
EID: 58149140385
PISSN: 15560864
EISSN: 15561380
Source Type: Journal
DOI: 10.1097/JTO.0b013e31818593fc Document Type: Editorial |
Times cited : (5)
|
References (7)
|